biontechq32022earningspr

3rd Quarter 2022 Financial Results & Corporate Update November 07, 2022 Exhibit 99.2

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY® where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after BioNTech's initial sales to national governments; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; competition from other COVID-19 vaccines or related to BioNTech's other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including those relating to additional formulations of BioNTech's COVID-19 vaccine, and BioNTech's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and BioNTech's research and development programs; the timing of and BioNTech's ability to obtain and maintain regulatory approval for BioNTech's product candidates; the ability of BioNTech’s COVID-19 vaccine to prevent COVID-19 caused by emerging virus variants; BioNTech's and its counterparties’ ability to manage and source necessary energy resources; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTech's development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for potential personal injury or death arising from the use of BioNTech's COVID-19 vaccine and other products and product candidates developed or manufactured by BioNTech; BioNTech's ability to progress BioNTech's Malaria, Tuberculosis and HIV programs, including timing for selecting clinical candidates for these programs and the commencement of a clinical trial, as well as any data readouts; the development of sustainable vaccine production and supply solutions on the African continent, including its BioNTainers, and the nature and feasibility of these solutions; BioNTech's estimates of research and development revenues, commercial revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, and shares outstanding; BioNTech's ability and that of BioNTech's collaborators to commercialize and market BioNTech's product candidates, if approved, including BioNTech's COVID-19 vaccine; BioNTech's ability to manage BioNTech's development and expansion; regulatory developments in the United States and foreign countries; BioNTech's ability to effectively scale BioNTech's production capabilities and manufacture BioNTech's products, including BioNTech's target COVID-19 vaccine production levels, and BioNTech's product candidates; and other factors not known to BioNTech at this time. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech's quarterly report on Form 6-K for the three and nine months ended September 30, 2022 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech’s current expectations and speak only as of the date hereof. This Slide Presentation Includes Forward-Looking Statements 2

COMIRNATY® ▼(the Pfizer-BioNTech COVID-19 vaccine) has been granted standard marketing authorization (MA) by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people aged 5 years and older. The vaccine is administered as a 2-dose series, 3 weeks apart. Adults and adolescents from the age of 12 are given 30 micrograms per dose; children aged 5 to 11 years are given 10 micrograms per dose. In addition, the MA has been expanded to include a booster dose (third dose) at least 3 months after the second dose in individuals 12 years of age and older. A third primary course dose may be administered at least 28 days after the second dose to people aged 5 years and older with a severely weakened immune system. The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has completed its rigorous evaluation of COMIRNATY, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available. In addition, COMIRNATY has also been granted standard MA for two adapted vaccines: COMIRNATY Original/Omicron BA.1, which contains mRNA encoding for the spike protein of the wild-type and of the Omicron BA.1 subvariant of SARS-CoV-2; and COMIRNATY Original/Omicron BA.4-5, which contains mRNA encoding for the spike protein of the wild-type and of the Omicron BA.4/BA.5 subvariant of SARS-CoV-2. COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may be administered as a booster in people aged 12 years and older who have received at least a primary vaccination course against COVID-19. There should be an interval of at least 3 months between administration of COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 and the last prior dose of a COVID-19 vaccine. IMPORTANT SAFETY INFORMATION: • Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine. • There is an increased, but very rare risk (<1/10,000 cases) of myocarditis and pericarditis following vaccination with COMIRNATY. These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general. The risk of myocarditis after a booster dose of COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 has not yet been characterized. • Rare cases of acute peripheral facial paralysis; uncommon incidence of insomnia, hyperhidrosis and night sweats; and unknown incidence of paraesthesia, hypoaesthesia and erythema multiforme have been identified in post-marketing experience. • Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions (e. g. dizziness, palpitations, increases in heart rate, alterations in blood pressure, tingling sensations and sweating) may occur in association with the vaccination process itself. Stress- related reactions are temporary and resolve on their own. Individuals should be advised to bring symptoms to the attention of the vaccination provider for evaluation. It is important that precautions are in place to avoid injury from fainting. • Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination. • As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals. • The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may be lower in immunosuppressed individuals. • As with any vaccine, vaccination with COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of the vaccine. • Adverse reactions observed during clinical studies are listed below according to the following frequency categories: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000). • Very common side effects: injection site pain, injection site swelling, tiredness, headache, muscle pain, chills, joint pain, diarrhea, fever • Common side effects: injection site redness, nausea, vomiting • Uncommon side effects: enlarged lymph nodes (more frequently observed after the booster dose), feeling unwell, arm pain, insomnia, injection site itching, allergic reactions such as rash or itching, feeling weak or lack of energy/sleepy, decreased appetite, excessive sweating, night sweats • Rare side effects: temporary one-sided facial drooping, allergic reactions such as hives or swelling of the face • Very rare side effects: inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis), which can result in breathlessness, palpitations or chest pain, anaphylaxis, extensive swelling of vaccinated limbs; facial swelling, pins and needles/tingling, reduced sense of touch or sensation, a skin reaction that causes red spots or patches on the skin • A large amount of observational data from pregnant women vaccinated with the initially approved COMIRNATY vaccine during the second and third trimester have not shown an increase in adverse pregnancy outcomes. While data on pregnancy outcomes following vaccination during the first trimester are presently limited, no increased risk for miscarriage has been seen. COMIRNATY can be used during pregnancy. No effects on the breast-fed newborn/infant are anticipated since the systemic exposure of breast-feeding woman to the initially approved COMIRNATY vaccine is negligible. Observational data from women who were breast-feeding after vaccination have not shown a risk for adverse effects in breast-fed newborns/infants. COMIRNATY can be used during breast-feeding. • No data are available yet regarding the use of COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 during pregnancy. Since differences between products are confined to the spike protein sequence, and there are no clinically meaningful differences in reactogenicity between those COMIRNATY variant adapted vaccines that have been clinically evaluated, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 can be used during pregnancy. • No data are available yet regarding the use of COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 during breast-feeding. Observational data from women who were breast-feeding after vaccination with the initially approved COMIRNATY vaccine have not shown a risk for adverse effects in breast-fed newborns/infants. COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 can be used during breast-feeding • Interactions with other medicinal products or concomitant administration of COMIRNATY, COMIRNATY Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 with other vaccines has not been studied. • Animal studies with COMIRNATY Original do not indicate direct or indirect harmful effects with respect to reproductive toxicity. • The safety of a COMIRNATY Original/Omicron BA.1 booster dose in individuals from 18 to ≤ 55 years of age is extrapolated from safety data from a subset of 315 adults 18 to ≤ 55 years of age who received a booster (fourth dose) of Omicron BA.1 30 µg (monovalent) after completing 3 doses of COMIRNATY. The most frequent adverse reactions in these participants 18 to ≤ 55 years of age were injection site pain (> 70%), fatigue (> 60%), headache (> 40%), myalgia (> 30%), chills (> 30%) and arthralgia (> 20%). • In a subset from the Phase 3 study, 305 adults > 55 years of age who had completed 3 doses of COMIRNATY, received a booster of COMIRNATY Original/Omicron BA.1 after receiving Dose 3. The overall safety profile for the COMIRNATY Original/Omicron BA.1 booster (fourth dose) was similar to that seen after the COMIRNATY booster (third dose). The most frequent adverse reactions in participants greater than 55 years of age were injection site pain (> 50%), fatigue (> 40%), headache 69 (> 30%), myalgia (> 20%), chills and arthralgia (> 10%). No new adverse reactions were identified for COMIRNATY Original/Omicron BA.1. • The safety of a booster dose of COMIRNATY Original/Omicron BA.4-5 is inferred from safety data for a booster dose of COMIRNATY Original/Omicron BA.1, as well as for a booster dose of COMIRNATY Original. • The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials. As with any vaccine, vaccination with Comirnaty Original/Omicron BA.1 or COMIRNATY Original/Omicron BA.4-5 may not protect all vaccine recipients • For complete information on the safety of COMIRNATY, COMIRNATY Original/Omicron BA.1 and COMIRNATY Original/Omicron BA.4-5, always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website. The black equilateral triangle ▼ denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. Individuals can help by reporting any side effects they may get. Side effects can be reported to EudraVigilance or directly to BioNTech using email medinfo@biontech.de, telephone +49 6131 9084 0, or via the website www.biontech.de Safety Information 3

Safety Information AUTHORIZED USE IN THE U.S. Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original And Omicron BA.4/BA.5) • Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is FDA-authorized under Emergency Use Authorization (EUA) for use in individuals 5 years of age and older as a single booster dose administered at least 2 months after either: • completion of primary vaccination with any authorized or approved monovalent* COVID-19 vaccine; or • receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. *Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus COMIRNATY® (COVID-19 Vaccine, mRNA) • COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 yrs of age and older. It is also authorized as a third primary series dose to individuals 12 years of age and older who have certain kinds of immunocompromise • The COVID-19 vaccine is FDA authorized under Emergency Use Authorization (EUA) for use in individuals 6 months and older to provide: • a 3-dose primary series to individuals 6 months through 4 years of age • a 2-dose primary series to individuals 5 years through 11 years of age • a third primary series dose to individuals 5 years through 11 years of age with certain kinds of immunocompromise EMERGENCY USE AUTHORIZATION Emergency uses of the vaccines have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and 5 years and older for the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. IMPORTANT SAFETY INFORMATION Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), COMIRNATY® (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine • Individuals should tell the vaccination provider about all of their medical conditions, including if they: • have any allergies • have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart) • have a fever • have a bleeding disorder or are on a blood thinner • are immunocompromised or are on a medicine that affects the immune system • are pregnant, plan to become pregnant, or are breastfeeding • have received another COVID-19 vaccine • have ever fainted in association with an injection • Individuals should not get COMIRNATY (COVID-19 Vaccine, mRNA), the Pfizer-BioNTech COVID-19 Vaccine, or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent if they have had a severe allergic reaction after a previous dose of COMIRNATY or the Pfizer-BioNTech COVID-19 Vaccine or any ingredient in these vaccines • There is a remote chance that these vaccines could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of the vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received the vaccine for monitoring after vaccination. If you experience a severe allergic reaction, call 9-1-1 or go to the nearest hospital The vaccine may not protect everyone. Side effects reported with the vaccine include: • Severe allergic reactions; Non-severe allergic reactions such as rash, itching, hives, or swelling of the face; Myocarditis (inflammation of the heart muscle); Pericarditis (inflammation of the lining outside the heart); Injection site pain; Tiredness; Headache; Muscle pain; Chills; Joint pain; Fever; Injection site swelling; Injection site redness; Nausea; Feeling unwell; Swollen lymph nodes (lymphadenopathy); Decreased appetite; Diarrhea; Vomiting; Arm pain; Fainting in association with injection of the vaccine; Unusual and persistent irritability; Unusual and persistent poor feeding; Unusual and persistent fatigue or lack of energy; Unusual and persistent cool, pale skin • Individuals should seek medical attention right away if they have any of the following symptoms: difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness • Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received COMIRNATY® (COVID-19 vaccine, mRNA) or Pfizer-BioNTech COVID-19 Vaccine. The observed risk is higher among adolescent males and adult males under 40 years of age than among females and older males, and the observed risk is highest in males 12 through 17 years of age. In most of these people, symptoms began within a few days following receipt of the second dose of vaccine. The chance of having this occur is very low • These may not be all the possible side effects of the vaccine. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away. Individuals should always ask their healthcare providers for medical advice about adverse events. Report vaccine side effects to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1‐800‐822‐7967 or report online to www.vaers.hhs.gov/reportevent.html. In addition, individuals can report side effects to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985 4

5 Corporate Outlook Ryan Richardson, Chief Strategy Officer Financial Results Jens Holstein, Chief Financial Officer COVID-19 Vaccine & Pipeline Update Özlem Türeci, Chief Medical Officer 3rd Quarter 2022 Highlights Ugur Sahin, Chief Executive Officer

Q3 Highlights: Corporate & Oncology Pipeline 1 BioNTech’s profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as well as the Quarterly Report as of and for the three and nine months ended September 30, 2022, filed as an exhibit to BioNTech’s Current Report on Form 6-K filed on November 7, 2022. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively 2 Collaboration with Genmab • Reported Q3 total revenues of €3.5 bn1 and year-to-date revenues of €13 bn1 • Raised full year 2022 revenue guidance to the upper end of our prior range: €16-17 bn • Signed letter of intent with Australia’s State of Victoria to establish an mRNA research and innovation center and clinical scale BioNTainer manufacturing facility • Expanded team to more than 4,000 employees around the world • Expanded Oncology pipeline to 19 clinical-stage programs in 24 ongoing clinical trials including five Phase 2 trials • Initiated Phase 1 clinical testing for three new programs: BNT116 (FixVac in NSCLC), BNT142 (RiboMab, CD3xCLDN6), BNT3132 (Hexabody, CD27) • Presented positive follow-up data from Phase 1/2 trial of CAR-T candidate BNT211 in solid tumors at ESMO Corporate Updates Oncology Pipeline Advancement 6

1 As of mid of October 2022; includes BA1- and BA4./5 bivalent adapted vaccines; - 2 Approved for prevention of COVID-19 as a 2-dose series in individuals 5 yrs of age and older and as a 3-dose series in individuals 6 months through 4 years of age; for all existing and future indications and formulations; - 3 COMIRNATY Original/Omicron BA.4/5 may be administered as a booster in people aged 12 years and older who have received at least a primary vaccination course against COVID-19; 4 Bivalent (Original and Omicron BA.4/BA.5) is FDA-authorized under Emergency Use Authorization (EUA) for use in individuals 5 years of age and older as a single booster dose administered at least 2 months after either completion of primary vaccination with any authorized or approved monovalent COVID-19 vaccine; or receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.; 5 Collaboration with Pfizer Q3 Highlights: COVID-19 Vaccine / COMIRNATY • First-to-market Omicron BA.4/BA.5-adapted bivalent vaccine • ~300 m doses of variant adapted vaccines invoiced1Strong global distribution Rapid regulatory advancement COMIRNATY (Original vaccine) Ongoing conversion to full approvals globally • Conversion to full marketing authorization in the EU2 • Label expansion in EU • 3 dose primary series in ages 6 months to <5 years • 3rd dose booster for ages 5-11 years • 4th dose booster for ages 12+ years Omicron BA.4/BA.5-adapted bivalent vaccine booster Approvals in 45+ countries or regions worldwide • EU: Full Marketing Authorization for ages 12+ years3 • US: FDA EUA for ages 5+ years4 Broad and diverse clinical program • Initiated Phase 2/3 trial of Omicron BA.4/BA.5-adapted bivalent booster in individuals 12+ and reported positive data from 18+ years cohorts at 30-day timepoint • Initiated Phase 1/2/3 trial of Omicron BA.4/BA.5-adapted booster in children 6 months to 11 years of age • Initiated Phase 1 trial with COMIRNATY / influenza combo mRNA vaccine5 7

Rapid Omicron Response: ~ 2 Months from Regulator Recommendation to Launch 1 as of October 25, 2022 VRBP = Vaccines and Related Biological Products; CMC = chemistry, manufacturing and controls; ICMRA = International Coalitions of Medicines Regulatory Agencies Clinical & preclinical data presented to VRBP Advisory Committee June 28 BA.1-adapted vaccine EMA submission July 19 FDA EUA for BA.4/BA.5- adapted vaccine (12+ yrs) August 31 EC approval for BA.1-adapted vaccine (12+ yrs) September 01 FDA EUA for BA.4/BA.5- adapted vaccine (5-11 yrs) FDA RECOMMENDS Omicron adapted bivalent vaccine encoding BA.4/BA.5 sublineages June 30 BA.4/BA.5- adapted FDA and EMA submission August 24 FIRST SHIPMENTS COMIRNATY BA.4/BA.5-adapted bivalent vaccine September 1 EC approval for BA.4/BA.5- adapted vaccine (12+ yrs) September 12 October 12 Ongoing Submissions, Approvals & Pediatric Label Expansion in Various GeographiesCMC/Manufacturing of BA.1 and BA.4/BA.5 Vaccine Product ~2 MONTHS Rapid deployment supports framework for sustainable vaccine business for COVID-19 and other infectious diseases Approved in 45+ countries and regions1 ICMRA recommends adaption of COVID- 19 vaccines to Omicron variant July 01 8

Epidemiology and Scientific Data Support Need for Omicron BA.4/BA.5-Adapted Bivalent Booster BA.4/BA.5 and sublineages continue to be dominant strains1 Original/Omicron BA.4/BA.5-adapted bivalent boosters may • Provide broad protection against currently circulating Omicron sublineages and the WT virus2 • Confer robust protection against future emerging Omicron sublineages or new VoCs that are closer to the WT virus2 1. WHO Website. www.who.int/en/activities/tracking-SARS-CoV-2-variants. Accessed 7 October 2022 2. Muik et al. Exposure to BA.4/BA.5 Spike glycoprotein drives pan-Omicron neutralization in vaccine-experienced humans and mice; bioRxiv 2022.09.21.508818 WT = wilt-type; VoC = variant of concern Original/Omicron adapted bivalent vaccines may enhance neutralization breadth • Expansion of memory B cells against epitopes shared broadly among variants • Expansion and preservation of T cell responses may protect against severe disease 9

Long-Term Need for Annually Adapted Boosters Anticipated Booster vaccination restores waning immunity5 Long-term health consequences of COVID-19 infections significant, but still not fully understood Continuous evolution of SARS-CoV-2 creates possibility of waves driven by new immune-evasive strains1,2,3 Risk remains high for severe COVID-19 in vulnerable populations3,4 Annual and/or with variant adapted vaccines expected for the foreseeable future 1 WHO Website. www.who.int/en/activities/tracking-SARS-CoV-2-variants. Accessed 7 October 2022 2 GISAID. https://gisaid.org/ Accessed 7 October 2022. 3 FDA VRBPAC. https://www.fda.gov/media/159491/download Accessed 7 October 2022 4 Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/6may2022 Accessed 7 October 2022 5 Goldberg Y, et al. N Engl J Med 2022; 386:2201-2212 DOI: 10.1056/NEJMoa211 10

Framework in Place for Building a Sustainable Business for COVID-19 and Multi-Product Opportunities in Other Infectious Diseases 11 Built on BioNTech’s validated platform of proven science, discovery, development, manufacturing & commercialization

12 Corporate Outlook Ryan Richardson, Chief Strategy Officer Financial Results Jens Holstein, Chief Financial Officer COVID-19 Vaccine & Pipeline Update Özlem Türeci, Chief Medical Officer 3rd Quarter 2022 Highlights Ugur Sahin, Chief Executive Officer

Multi-Pronged Strategy for Continued Innovation 13 Vaccine Boosters to Address Evolving Virus Vaccine for Seasonal Protection with Convenient Single-Dose Administration Vaccines Designed for Extended Durability and Breadth of Protection Innovation supported by insights from continuous variant surveillance and robust clinical program

Omicron BA.4/BA.5-Adapted Bivalent Vaccine Approved in 45+ Countries1 14 FDA EUA2 EC Marketing Authorization3 FDA Submission EMA Submission Phase 1/2/3 Clinical Trial BA.4/5-Adapted Ages 12+ yrs Ongoing4 Ages 5-11 yrs Ongoing5 Ages 6 mo-4 yrs Planned for 1Q 2023 Planned for 1Q 2023 Ongoing5 BA.1-Adapted Ages 12+ yrs 1 As of October 25, 2022 2 Bivalent (Original and Omicron BA.4/BA.5) is FDA-authorized under Emergency Use Authorization (EUA) for use in individuals 5 years of age and older as a single booster dose administered at least 2 months after either completion of primary vaccination with any authorized or approved monovalent COVID-19 vaccine; or receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine; 3 COMIRNATY Original/Omicron BA.4/5 or COMIRNATY Original/Omicron BA.1 and may be administered as a booster in people aged 12 years and older who have received at least a primary vaccination course against COVID-19; 4 Phase 2/3 trial of Omicron BA.4/BA.5 adapted bivalent booster in individuals 12+ years old 5 Phase 1/2/3 trial of Omicron BA.4/BA.5 adapted booster in children 6 months – 11 years of age

Positive Data from 30 Day Time Point in Omicron BA.5/BA.5-Adapted Vaccine Study Omicron BA.4/BA.5-adapted bivalent vaccine substantially increased Omicron BA.4/BA.5 neutralizing antibody titers above pre-booster levels in adults 18+ 15 Randomized, controlled, Phase 2/3 trial in healthy volunteers aged 12 and older Updated data from sentinel cohort >18 years Study design: • N=900 • Previously received at least 3 vaccine doses • Ages 18+: 30-µg or 60-µg booster • Ages 12-17: 30-µg booster • Original vaccine served as comparator arm Primary endpoints: • Safety, tolerability and immunogenicity Sentinel cohort (n=40/group): • Bivalent Original/BA.4/5 30-µg: 18-55 years of age • Bivalent Original/BA.4/5 30-µg: >55 years of age • Comparator group: Original BNT162b2 30-µg (>55 years of age) Safety and tolerability profile of bivalent booster remains favorable and similar to original vaccine

Omicron BA.4/BA.5 Adapted Bivalent Vaccine Demonstrates Strong Immune Response in Adults 18+ Improved responses with bivalent vaccine most pronounced in elderly and baseline negative individuals Vaccine Group (as randomized) BNT162b2 Bivalent (WT/OMI BA.4/BA.5)1 30 μg BNT162b21 30 μg Age 18-55 Years >55 Years >55 Years Assay Sampling time point: 1 month Baseline SARS-CoV-2 Status n GMFR (95% CI) n GMFR (95% CI) n GMFR (95% CI) SARS-CoV-2 FFRNT – Omicron BA.4/BA.5 - NT50 (titer) All 38 9.5 (6.7, 13.6) 36 13.2 (8.0, 21.6) 40 2.9 (2.1, 3.9) Positive 20 6.0 (3.5, 10.1) 19 6.7 (3.5, 12.7) 20 2.8 (1.9, 4.1) Negative 18 16.0 (10.8, 23.7) 17 28.3 (15.2, 52.8) 20 3.0 (1.8, 4.9) SARS-CoV-2 FFRNT – reference strain - NT50 (titer) All 38 5.1 (3.5, 7.3) 36 5.8 (3.9, 8.6) 40 3.0 (2.1, 4.3) Positive 20 3.1 (2.0, 4.9) 19 3.5 (2.1, 6.0) 20 2.0 (1.4, 2.9) Negative 18 8.8 (5.4, 14.4) 17 10.2 (6.3, 16.6) 20 4.4 (2.3, 8.2) 16 1 Collaboration with Pfizer FFRNT = fluorescent focus reduction neutralization test; GMFR = geometric mean fold rise

Initiated Phase 1 Combination Trial of Influenza mRNA Vaccine + Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine1 17 Quadrivalent Influenza (qFlu) modRNA vaccine (2 type A strains, 2 type B strains selected annually) Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine 30 µg qFlu 30 µg Omicron BA.4/BA.5 30 µg qFlu 60 µg Omicron BA.4/BA.5 60 µg qFlu 30 µg Omicron BA.4/BA.5 30 µg qFlu 60 µg qFlu ~180 adults aged 18-64 Primary endpoints: safety, tolerability and immunogenicity Standard of Care Flu Vaccine (control arm) N=30 + 1 Trial being conducted by Pfizer as part of ongoing collaboration Flu + COVID-19 vaccine combination may offer convenient seasonal administration for protection in a single shot + + +

Next Generation Vaccine Approaches to Provide Durable, Broad Protection Constructs designed to engage different arms of the immune system including antibodies and T cells 18 Targets highly-conserved non-spike proteins and aims to • Increase immune resilience • Enhance and broaden T cell response • Provide memory T cell persistence • Enhance B cell response durability Multiple candidates being explored • Designed to elicit more broadly neutralizing antibodies • Potential to protect against multiple, not-yet-seen coronavirus variants • Potential to be combined with T cell enhancing vaccine + BNT162b4: T Cell Enhancing Vaccine Candidate Omicron BA.4/BA.5-adapted bivalent vaccine Engineered Spike Protein Vaccines Additional trial initiations planned for: Start Phase 1 expected in 4Q 2022: BNT162b4Engineered spike protein candidates

Infectious Disease Pipeline: Multiple Opportunities Built on Proven Platform 1 Collaboration with Pfizer 2 University of Pennsylvania collaboration 3 Collaboration with Bill & Melinda Gates Foundation. BioNTech holds worldwide distribution rights except developing countries where BMG holds distribution rights. Indication Product candidate Pre-clinical Phase 1 Phase 2 Phase 3 Commercial Milestones 2022 COVID-191 COMIRNATY® BNT162b2(Original/Omicron BA.4/BA.5-adapted bivalent) Launch + Data updates BNT162b2 (Original/Omicron BA.1-adapted bivalent) Launch + Data updates BNT162b4 (T cell enhancing) Start Phase 1: 4Q 2022 BNT162b5 (Enhanced spike antigen) Phase 2 started in July 2022 Covid-19 – Influenza combination1 BNT162b2+BNT161 (qFlu + BA.4/BA.5-adapted bivalent) Phase 1 initiated in October 2022 Influenza1 BNT161 Data update in July 2022 Phase 3 started in September 2022 Shingles1 Un-named program Start Phase 1: 4Q 2022 HSV 22 BNT163 Start Phase 1: 4Q 2022 Tuberculosis3 BNT164 Start Phase 1: early 2023 Malaria BNT165 Start Phase 1: 4Q 2022 / early 2023 HIV3 Un-named program Additional mRNA vaccine programs3 Un-named programs Precision antibacterials Un-named programs mRNA vaccines partnered w/Pfizer 10+ other infectious disease programs ✓ ✓ ✓ 19 ✓ ✓

Oncology Pipeline: Significant Progress and Expansion in 2022 1 Collaboration with Genentech, a member of the Roche Group 2 Investigator-initiated Phase 1 trial FPD = First patent dosed, SMIM = small molecule immunomodulators, NSCLC = non-small cell lung cancer 20 Drug class Platform Product candidate Indication (targets) Pre-clinical Phase 1 Phase 2 Phase 3 Milestones mRNA FixVac BNT111 Advanced and R/R melanoma BNT112 Prostate cancer BNT113 HPV16+ head and neck cancer BNT116 NSCLC 2L+ FPD in July 2022 iNeST Autogene cevumeran (BNT122)1 1L melanoma Data update exp. 1H 2023 Adjuvant colorectal cancer Solid tumors Adjuvant pancreatic ductal adenocarcinoma2 Data update June 2022 Intratumoral immunotherapy SAR441000 (BNT131) Solid tumors (IL-12sc, IL15-sushi, GM-CSF, IFNα) RiboMabs BNT141 Multiple solid tumors (CLDN18.2) FPD in Jan. 2022 BNT142 Multiple solid tumors (CD3×CLDN6) FPD in July 2022 RiboCytokines BNT151 Multiple solid tumors (optimized IL-2) BNT152, BNT153 Multiple solid tumors (IL-7, IL-2) Cell therapies CAR T cells + CARVac BNT211 Multiple solid tumors (CLDN6) Data update Sept. 2022 BNT212 Pancreatic, other cancers (CLDN18.2) Neoantigen-based T cells BNT221 Multiple solid tumors TCR engineered T cells To be selected All tumors Antibodies Next-gen immune checkpoint modulators GEN1046 (BNT311) Metastatic NSCLC (PD-L1×4-1BB) Multiple solid tumors (PD-L1×4-1BB) GEN1042 (BNT312) Multiple solid tumors (CD40×4-1BB) Data update 4Q 2022 GEN1053 (BNT313) Malignant solid tumors (CD27) Initiated in Nov. 2022 Targeted cancer antibodies BNT321 Pancreatic cancer (sLea) SMIM Toll-like receptor binding BNT411 Solid tumors (TLR7) ✓ ✓ ✓ ✓ ✓ ✓

BNT211: CAR-T Cell Program with Potential Targeting Multiple High-Need Solid Tumors Reinhard K, et al. Science 2020; 367:446-453 CLDN6 = Claudin-6; CAR-T cells = chimeric antigen receptor engineered T cells; scFv = single chain variable fragment; RP2D = recommended Phase 2 dose; NOS = not otherwise specified; Patients with CLDN6+ relapsed/refractory solid tumors (up to 36 patients) Part 1: monotherapy CLDN6 CAR-T dose escalation: 1x107 CAR-T (DL1) 1x108 CAR-T (DL2) 1x109 CAR-T (DL3) Part 2: combination therapy CLDN6 CAR-T dose escalation + CLDN6 CARVac: 1x107 CAR-T (DL1) 1x108 CAR-T (DL2) 1x109 CAR-T (DL3) RP2D High CLDN6 expression Part 3 Expansion Cohorts • Ovarian Cancer • Testicular Cancer • Endometrial Cancer • Lung Cancer • Gastric Cancer • Tumors NOS 2nd generation CAR • Directed against CLDN6 • Cancer specific carcino-embryonic antigen • Expressed in multiple solid cancers with high medical need CARVac • Drives in vivo expansion, persistence and efficacy of CAR-T cells CLDN6 not present in healthy tissues CLDN6 expressed in multiple cancers GEN1046 / BNT3111 21

CLDN6 CAR-T cells as monotherapy or combined with CARVac well tolerated at dose levels evaluated to date (1x107 and 1x108 CAR-T) • Mostly grade 1-2 CRS seen in 45% of patients, manageable by administration of tocilizumab if needed • 2 DLTs observed, both patients fully recovered and showed clinical benefit • MTD not reached yet Dose-dependent expansion of CAR-T cells achieved in all patients translating into clinical activity: ORR 33%, DCR of 67% in evaluable patients (n=21; 1x107 and 1x108 CAR-T)1 • 1 CR, 6 PR, 7 SD Testicular cancer patients (n=7)2 with particularly encouraging responses at 1x108 CAR-T: • ORR 57%, DCR 85% • 1 CR, 3 PR, 2 SD Safety BNT211: Follow-up Data of Novel CAR-T Cell Program in Solid Tumors Presented at ESMO 2022 22 Efficacy BNT211 continues to show encouraging efficacy and safety profiles 1 Including lymphodepletion free cohort; 2 Excluding lymphodepletion free cohort Data cut-off: August 16, 2022 DL1: 1x107 CAR-T; DL2: 1x108 CAR-T CLDN6 = Claudin-6; DLT = dose-limiting toxicity; MTD = maximum tolerated dose; CRS = cytokine release syndrome; CR = complete response; DCR = disease control rate; DL = dose level; ORR = overall response rate; PR = partial response; RP2D = recommended Phase 2 dose; SD = stable disease

Dose Dependent CAR-T Expansion Seen in All Patients 23 0 50 100 150 200 250 300 350 104 105 106 107 108 109 1010 Days post infusion T o ta l C A R -T c o u n ts 6 12 18 24 30 360 Weeks post infusion 42 48 LLOQ DL2 Part 1 Part 2 0 5 0 1 0 0 1 5 0 2 0 0 2 5 0 3 0 0 3 5 0 1 0 4 105 106 107 108 109 1010 Days post infusion T o ta l C A R -T c o u n ts 6 12 18 24 30 360 Weeks post infusion 42 48 DL1 Re-dosing 50% LD CR DL1 (1x107 CLDN6 CAR-T) DL2 (1x108 CLDN6 CAR-T) Strong persistence of CAR-T observed for more than 100 days, with some patients showing persistence for more than 200 days Two patients were treated with CAR T without prior LD and engraftment was unsuccessful. *Redosing without prior LD Data cut-off: 15 Jun 2022. CR = complete response; DL = dose level; LD = lymphodepletion; LLOQ = lower limit of quantification. *

Robust Tumor Shrinkage and Durable Responses observed in Testicular Cancer Patients 24 Data cut-off: 16 Aug 2022. CR = complete response; DCR = disease-control rate; DL = dose level; LD = lymphodepletion; ORR = overall response rate. Grey lines indicate patients w/o LD. Red lines indicate ongoing assessments. Selected scans of responses in various patients • One testicular cancer patient investigator-assessed as CR after 12 weeks (metabolic response in PET-CT and tumor-marker negative) • CR confirmed at 18 and 52 weeks Pre- Post- Part 2 DL1 Pat#3 Part 1 DL2 Pat#3 Part 1 DL2 Pat#4 Deepening of responses over time 0 4 8 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8 5 2 -1 0 0 -8 0 -6 0 -4 0 -2 0 0 2 0 4 0 6 0 w e e k s C h a n g e i n t a rg e t s u m [ % ] 46 weeks (Part1 DL2 Pat#4) 36 weeks (Part2 DL2 Pat#7) 30 weeks (Part2 DL2 Pat#4) DL1 w/ LD DL2 w/ LD Total w/ LD Testicular, n 4 7 11 ORR, % 25 57 45 DCR, % 25 85 54 CR

Rapid Advancement of Next Generation Immuno-Modulators for Cancer 1 Collaboration with Genmab based on 50/50 sharing of costs and profits 2 HexaBody® technology owned by Genmab Designed to prime and activate anti-tumor T cell and Natural Killer cell function Phase 1/2: Advanced solid tumors • Data update at ESMO I/O 2022 GEN1042 / BNT3121 Phase 2: R/R NSCLC Phase 1/2: Advanced solid tumors GEN1046 / BNT3111 Phase 1/2: Solid tumors • Initiated Phase 1/2 in November • Preclinical data and MOA at SITC 2022 GEN1053 / BNT3131 Bispecific antibody: Conditional 4-1BB co-stimulation while blocking PD-(L)1 axis Bispecific antibody: Combines targeting and conditional activation of CD40 and 4-1BB on immune cells Monospecific HexaBody2 targeting CD27 on naïve and activated T cells 25

26 Corporate Outlook Ryan Richardson, Chief Strategy Officer Financial Results Jens Holstein, Chief Financial Officer COVID-19 Vaccine & Pipeline Update Özlem Türeci, Chief Medical Officer 3rd Quarter 2022 Highlights Ugur Sahin, Chief Executive Officer

Key Highlights for 3Q 2022 27 Total Revenues1 Operating Result €3.5 bn €2.4 bn €13.4 bn + €7.3 bn€6.98 Diluted EPS Cash and Trade Receivables 1 BioNTech’s profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as well as the Quarterly Report as of and for the three and nine months ended September 30, 2022, filed as an exhibit to BioNTech’s Current Report on Form 6-K on November 7, 2022. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.

28 €3.4 bn Q3 2022 €2.5 bn €0.6 bn €0.3 bn €12.9 bn YTD 2022 €9.1 bn €2.3 bn €1.5 bn 3Q and YTD 2022 COVID-19 Vaccine Revenues 3Q 2022 revenues in line with our expectations Direct COVID-19 vaccine sales to customers in BioNTech’s territory Share of gross profit from COVID-19 vaccine sales in the Pfizer and Fosun Pharma territory (100% gross margin)1 COVID-19 vaccine sales to collaboration partners of products manufactured by BioNTech 1 BioNTech’s profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as well as the Quarterly Report as of and for the three and nine months ended September 30, 2022, filed as an exhibit to BioNTech’s Current Report on Form 6-K on November 7, 2022. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively. 3Q 2022 YTD 2022

(in millions, except per share data)1 Three months ended September 30, Nine months ended September 30, 2022 2021 2022 2021 Commercial revenues2 €3,394.8 €6,040.1 €12,923.3 €13,348.1 Research & development revenues 66.4 47.2 109.0 96.1 Total revenues €3,461.2 €6,087.3 €13,032.3 €13,444.2 Cost of sales (752.8) (1,211.4) (2,811.5) (2,328.3) Research and development expenses (341.8) (260.4) (1,027.2) (677.7) Sales and marketing expenses (12.8) (10.5) (44.9) (32.5) General and administrative expenses (141.0) (68.2) (361.8) (154.9) Other operating income less expenses 174.7 186.7 562.9 333.3 Operating income €2,387.5 €4,723.5 €9,349.8 €10,584.1 Finance income less expenses 56.6 (56.1) 431.7 (251.6) Income taxes (659.2) (1,456.4) (2,625.8) (3,206.2) Profit for the period €1,784.9 €3,211.0 €7,155.7 €7,126.3 Earnings per share Basic profit for the period per share €7.43 €13.14 €29.47 €29.22 Diluted profit for the period per share €6.98 €12.35 €27.70 €27.46 3Q and YTD 2022 Financial Results – Profit or Loss 29 1 Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context. Presentation of the consolidated statements of profit or loss has been condensed. 2 BioNTech’s profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as well as the Quarterly Report as of and for the three and nine months ended September 30, 2022, filed as an exhibit to BioNTech’s Current Report on Form 6-K on November 7, 2022 . Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively.

2022 Financial Year Guidance Update 30 COVID-19 Vaccine Revenues for FY 20221 Estimated BioNTech COVID-19 vaccine revenues € 16 – 17 bn (previously € 13 – 17 bn) Planned FY 2022 Expenses and Capex1 R&D expenses € 1,400 - 1,500 m SG&A expenses € 450 - 550 m Capital expenditure € 450 - 550 m Estimated FY 2022 Tax Assumptions BioNTech Group estimated annual effective income tax rate ~27% (previously ~28%)2 1 Ranges reflect current base case projections and do not include potential effects caused by or driven from additional collaborations or potential M&A transactions. 2 BioNTech Group estimated annual effective income tax rate decreased from 31.6% (FY 2021) to ~27% (FY 2022) due to decreasing average trade tax rates and one-time effect resulting from share-based payment expenses.

Share Repurchase Program 31 Period Number of acquired ADS Percentage of share capital1 Average price (in $) Volume (in million $) May 2, 2022 to October 10, 2022 6,945,513 2.8% 143.98 1,000.0 1 For the share repurchase, the "percentage of share capital" ratio is calculated based on the shares issued as of April 30, 2022 (248,552,200 ordinary shares). • Repurchase American Depositary Shares (ADS) in the amount of up to $ 1.5 bn • Term of up to two years • Repurchased ADSs are to be used in whole or in part to satisfy upcoming settlement obligations under share-based payment arrangements • First tranche worth up to $ 1 bn began May 2, 2022, and ended October 10, 2022 • Second tranche worth up to $ 0.5 bn commencing December 7, 2022, has been approved in November

32 Corporate Outlook Ryan Richardson, Chief Strategy Officer Financial Results Jens Holstein, Chief Financial Officer COVID-19 Vaccine & Pipeline Update Özlem Türeci, Chief Medical Officer 3rd Quarter 2022 Highlights Ugur Sahin, Chief Executive Officer

2022 year-to-date recap Outlook for COVID-19 Vaccine Franchise 1 Distribution of COVID-10 vaccine in collaboration with Pfizer 2 As of mid of October 2022; includes BaA1- and BA4./5 bivalent adapted vaccines ~300 m variant adapted vaccine doses invoiced since August 2022 with approvals in >45 countries or territories1,2 Full-year 2022 deliveries: • Up to 2.1 bn doses expected to be invoiced globally • Expect to fulfill 105 m dose US contract and 650 m dose EU contract by year-end 2023/24 market outlook: • Hybrid public-private market expected to develop in 2023 and beyond • United States market to shift to commercial model as early as 1Q 2023, with list price between $110 - $130 expected per single dose vial for adults • Global demand expected to be second-half weighted, driven by seasonality of vaccine administration 33 Outlook for Full Year 2022 and beyond

Select COVID-19 and Infectious Disease Pipeline Milestones 1 Partnered with Pfizer 2 University of Pennsylvania collaboration 3 Collaboration with BMGF HSV 2 = Herpes simplex virus type 2; FPD = first patient dosed 34 2023 Outlook Up to 5 new Infectious Disease trial initiations Program Milestone Anticipated Timeline COVID-19 BNT162b2 + BNT161 (BA.4/BA.5-adapted bivalent + qIRV) Phase 1 FPD November 2022 BNT162b5 (Enhanced spike antigen)1 Phase 2 data 4Q 2022 BNT162b4 (T cell enhancing)1 Phase 1 FPD 4Q 2022 Additional next-generation vaccines1 Multiple Phase 1 trials 4Q 2022 Other BioNTech-Pfizer collaboration programs mRNA Shingles vaccine1 Phase 1 FPD 4Q 2022 Other BioNTech Infectious Disease vaccine programs BNT163 (mRNA HSV2 vaccine)2 Phase 1 FPD 4Q 2022 BNT164 (mRNA tuberculosis vaccine)3 Phase 1 FPD early 2023 BNT165 (mRNA malaria vaccine) Phase 1 FPD 4Q 2022 / early 2023

Select Oncology Pipeline Milestones 1 Collaboration with Genmab 2 Trial sponsored by Regeneron 3 Collaboration with Genentech, a member of the Roche group 35 2023 Outlook Up to 10 Oncology clinical trial updates Program Milestone Anticipated Timeline First-in-Human Trial Starts BNT313 (GEN1053) Phase 1/2 in solid tumors FPD1 November 2022 BNT116 FixVac Phase 1/2 in 1L NSCLC in combo with cemiplimab FPD2 4Q 2022 Data Updates BNT312 (GEN1042) Phase 1/2 in solid tumors data1 ESMO IO 2022 Autogene cevumeran / BNT122 (iNeST) Phase 2 in combo with pembrolizumab in frontline melanoma data3 1H 2023

2023 Outlook Once in a generation opportunity to transform medicine 36 Focused on creating long-term value to patients, shareholders and society Expand reach of vaccine franchise and deliver data for next- generation candidates Catalyst-heavy 2023 expected with multiple late-stage data readouts and FIH trial starts Re-investing to transform capabilities, accelerate organic growth complemented by bolt-on BD/M&A

THANK YOU